Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT

Cisplatin (Cis-DDP) is one of the most widely used anti-cancer drugs. It is applicable to many types of cancer, including lung, bladder, and breast cancer. However, its use is now limited because of drug resistance. p90 ribosomal S6 kinase (p90RSK) is one of the downstream effectors in the extracell...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yujin, Huynh, Diem Thi Ngoc, Kang, Keon Wook, Myung, Chang-Seon, Heo, Kyung-Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941763/
https://www.ncbi.nlm.nih.gov/pubmed/31818359
http://dx.doi.org/10.5483/BMBRep.2019.52.12.234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941763/
https://www.ncbi.nlm.nih.gov/pubmed/31818359
http://dx.doi.org/10.5483/BMBRep.2019.52.12.234

Ejemplares similares